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Abstract
Oestrogen modulates cognitive function and affective behaviours subserved by the prefrontal cortex
(PFC). Identifying and localising oestrogen receptor (ER)α, in human PFC will contribute to our
understanding of the molecular mechanism of oestrogen action in this region. Inferences about the
site of action of oestrogen in human brain are derived largely from studies performed in nonhuman
mammalian species; however, the congruence of findings across species has not been demonstrated.
Furthermore, the laminar, cellular, and subcellular localisation of ERα in the cortex is debated.
Therefore, we compared the distribution of ERα in human dorsolateral prefrontal cortex (DLPFC)
with that of monkey DLPFC and rat medial PFC. Immunohistochemistry performed on frontal cortex
from the three species demonstrated ERα positive cells throughout all layers of the PFC, in pyramidal
and nonpyramidal neurones, with both nuclear and cytoplasmic immunoreactivity. Western blot
analyses and preabsorption studies confirmed that the antibody used recognised ERα and not ERβ.
A strong ERα immunoreactive band corresponding to the full-length ERα protein (65–67 kDa) in
the frontal cortex of all three species matched the size of the predominant immunoreactive band
detected in breast cancer cell lines known to express ERα. Additionally, other ERα immunoreactive
proteins of varying molecular weight in breast cancer cells, rat ovary and mammalian brain were
detected, suggesting that ERα may exist in more than one form in the mammalian frontal cortex. The
present study provides evidence that ERα protein exists in neurones in mammalian PFC and that
ERα is anatomically well-positioned to directly mediate oestrogen action in these neurones.
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Early studies of the effects of oestrogen on the central nervous system focused largely on the
hypothalamus, given the role of oestrogen in the regulation of reproduction (1). In the past two
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decades, a number of studies have shown that oestrogen and its receptors are located in diverse
brain regions and have functions within the mammalian cortex outside of areas directly
involved in reproduction (2–4). A range of cognitive processes are modulated by oestrogen,
including working memory (5,6). The prefrontal cortex (PFC) plays a critical role in working
memory and executive function (e.g. planning, problem solving, behavioural inhibition), in
maintaining representations of stimuli over time to guide behaviour, and in interpreting
affective valence and motivational context (7). Several studies suggest that oestrogen or
oestrogen-like components modulate human dorsolateral prefrontal cortex (DLPFC) activity
in both males and females, as deduced from behavioural and imaging paradigms examining
working memory (6,8,9), although an absence of any beneficial effects of oestrogen on
cognitive performance has also been found (10).
Despite the mounting clinical evidence of an effect of oestrogen on PFC cognition, it is still
not clear whether oestrogen acts through the classical activation pathway via the receptors,
oestrogen receptor (ER)α and ERβ, to mediate these effects in human prefrontal cortex. ERα
and ERβ, in the absence or presence of oestrogen, can modulate the transcription of target
genes (11). Seminal studies showed that the mammalian cortex can bind oestrogen (12,13);
however, the molecular substrate of these oestrogen-binding sites in specific areas of the cortex
is still actively debated. Further adding to the complexities in delineating the role of oestrogen
in cortical processes is the lack of agreement in findings about which receptor subtype is
involved and about which particular brain cell type or cortical layer is directly impacted by
oestrogen.
ERα mRNA has been detected in the monkey prefrontal cortex (2,15), and localised in neurones
of the human DLPFC and hippocampus (16). In the rodent PFC, ERα mRNA is expressed at
low levels throughout the cerebral cortex but is more pronounced in deeper layers V and VI
(17). The existence of cortical ERα mRNA suggests that ERα protein should be present in
frontal cortical neurones; however, considerable controversy regarding the abundance and the
cellular localisation of cortical ERα protein exists. Additionally, it has been shown that there
are a number of ERα mRNA exon-deleted variants within the frontal cortex that could
potentially produce different ERα proteins with altered functions (18). These ERα mRNA
variants translate into ERα variant proteins with distinct cellular localisations and thereby could
impact the biological response of cortical neurones to oestrogen (19). These ERα variant
proteins may also differ in their ability to be recognised by different antibodies depending on
epitope recognition site, further complicating the interpretation of the presence of ERα via
immunodetection.
To determine whether ERα protein could be a molecular mediator of oestrogen action in human
prefrontal cortex neurones, and whether apparent species variations in the cortical localisation
of ERα are due to methodological differences or true species differences, we asked the
following questions: (i) can we detect neuronal ERα protein in the human, monkey and rodent
PFC using the same methodology; (ii) is the anatomical distribution/expression comparable
among these three species; and (iii) do the molecular weights of ERα immunoreactive bands
vary among these three species? Understanding whether oestrogen can act directly on neurones
within the DLPFC via ERα, will impact our current models of the molecular mechanisms of
oestrogen action in cortex and may help uncover novel pathways for pharmacological
intervention in disorders of executive function and emotional processing.
Materials and methods
Brain collection
Experiments were performed on brains from male subjects of three species: rat (n = 5, Sprague–
Dawley, mean age = 90 days), nonhuman primate (n = 5, Macaca mulatta, mean age = 7.5
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years) and human (n = 7, nonpsychiatric subjects, mean age = 43 years, average post-mortem
interval = 21.6 h). The tissue collected from the subjects used was obtained under an approved
NIMH protocol for human tissue, and the animal tissue was obtained following strict adherence
to the guidelines of the animal care and use committee under approved NIMH protocols. Only
male subjects were used to avoid the possibility of variance imposed by differences in the
amount of ERα as a result of varying levels of reproductive steroids in females. Rats were
euthanised by CO2 gas and the brains immediately removed, chilled in ice cold saline, coronally
sliced, and fresh frozen in isopentane (−40 °C). The nonhuman primates were anaesthetised
with an overdose of sodium pentobarbital and transcardially perfused with 1 l of 0.9% saline.
The brains were quickly removed, chilled in ice cold saline, cut into 1-cm coronal slabs, and
fresh frozen in isopentane (−40 °C). In both species, the tissue was stored frozen (−80 °C) until
cryostat processing.
Post-mortem human brains were obtained and organised under the authorities of the Office of
the Chief Medical Examiner in Washington, DC and the Clinical Brain Disorders Branch of
the National Institute of Mental Health (NIMH, Bethesda, MD, USA). Briefly, after autopsy
retrieval, the brain was chilled in wet ice, coronally sliced into slabs approximately 1 cm in
thickness, quickly frozen in a slurry of isopentane and dry ice (−40 °C), then stored frozen at
−80 °C until cryostat processing (20). For cryostat-sectioning from blocks of normal human
brain, tissue was dissected from the middle frontal gyrus (for human subject characteristics,
see Table 1). For a comparison of ERα staining patterns across the brain, we simultaneously
stained tissue from the prefrontal cortex, our region of interest, along with frozen sections from
normal human mesial temporal lobe blocked at the mid-body of the hippocampus, a region
known to express high levels of ERα (n = 2, nonpsychiatric subjects, mean age = 64 years,
average post-mortem interval = 30.3 h) and the lateral cerebellar hemisphere blocked parallel
to the vermis containing follia of the cerebellar cortex, a region known to express low levels
of ERα (n = 2, nonpsychiatric subjects, mean age = 43 years, average post-mortem interval =
20.5 h). All blocks were cut coronally at 14 µm, thaw-mounted on gelatine-coated slides, and
stored at −80 °C.
Area of analysis
The region of interest for this study is Brodmann’s area 46 (BA46) of the DLPFC in human
and monkey (Fig. 1A, B) because it is integral to working memory. BA46 was defined using
Nissl-stained sections based on established cytoarchitectural criteria. Briefly, BA46 is defined
as: (i) the presence of a well-defined granular layer IV; (ii) columnar arrangement of pyramidal
neurones in layer III; (iii) an increase in size of pyramidal neurones from superficial layer III
to deep layer III; (iv) a similar size of pyramidal neurones in deep layer III and layer V; and
(v) a clear transition from layer VI to the white matter. BA46 is not clearly delineated in the
rat therefore we chose to examine part of the medial prefrontal cortex, the infralimbic region
and cingulate cortex areas 1 and 3 (Fig. 1C). The brain regions that loosely define the prefrontal
cortex in the rat are based on their neuronal connections to the mediodorsal thalamic nuclei
(e.g., the anterior cingulate, agranular insular, orbitofrontal area, the medial precentral area,
and infralimbic region).
Primary anti-ERα antibody
We chose to use mouse anti-human ERα monoclonal antibody, ER6F11 (Novocastra
Laboratories, Newcastle upon Tyne, UK) as the primary antibody. The antibody binds to an
epitope at the N-terminus of the ER protein between amino acids 1–184, produces robust
labelling in fresh frozen human tissues (21), and will detect ER protein of other species
including monkey, rabbit, rat, mouse and quail (per Novocastra). In addition, we performed
several experiments to provide a more detailed characterisation of this antibody in brain. We
tested a series of antibody dilutions in the range 1 : 20 to 1 : 100, as recommended by the
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manufacturer, to determine the antibody concentration necessary to produce a reliable stain in
fresh frozen human DLPFC and mesial temporal lobe tissue. A fairly high concentration is
needed to attain a robust immunoreaction in our protocol (see below). To validate the ERα
labelling pattern seen with the Novocastra antibody, a second ERα antibody, Santa Cruz
Biotechnology’s H-184 (sc-7202; Santa Cruz, CA, USA), a rabbit polyclonal raised against
amino acids 2–185 of ERα of human origin and recommended for detection of oestrogen
receptor of mouse, rat and human origin, was tested via immunohistochemistry in human
DLPFC at a dilution of 1 : 40 (recommended 1 : 50). To further test the specificity of the
ER6F11 antibody, we incubated full-length, human recombinant ER proteins, ERα or ERβ,
with the primary antibody prior to immunolabelling. To ensure that both antibody and
recombinant proteins were adequate for detection of the species used, we also performed a
sequence alignment between human, macaque and rat, and found that there is a 99.4% sequence
homology between human and macaque and 84.2% homology between human and rat (see
Preabsorption study). Finally, we determined the specificity of the antibody for ERα by
performing western blotting techniques with recombinant ERα versus ERβ proteins and by
immunoprecipitation experiments (see Immunoprecipitation and Western blot analysis
studies).
Immunohistochemistry
Slide-mounted tissues from all three species were thawed for 20 min at room temperature (RT),
then fixed in 4% paraformaldehyde [in phosphate-buffered saline (PBS), 1 mM NaOH, 12 mM
NaH2PO4, 154 mM NaCl, pH 7.4] for 10 min at room temperature. Slides were rinsed 3 × 5
min with PBS and placed in 75% MeOH + 0.75% H2O2 solution for 20 min at RT to block
endogenous peroxidase activity. Slides were rinsed (3 × 5 min) with PBS and incubated with
10% normal horse serum in diluent [0.05% bovine serum albumin (BSA), 0.3% triton X-100
in PBS] for 1 h at RT to block nonspecific binding. ERα primary antibody was applied overnight
at 4 °C (ER6F11 used at a 1 : 20 dilution in diluent). After rinsing 3 × 5 min in PBS, slides
were incubated with a horse anti-mouse IgG biotinylated secondary antibody (Vector
Laboratories, Burlingame, CA, USA) at a 1 : 100 dilution in diluent for 1 h at RT and rinsed
again 3 × 5 min in PBS. For rat sections, a horse anti-mouse IgG biotinylated secondary
antibody that was pre-absorbed against rat IgG (1 : 100 dilution; Vector Laboratories) was
used. This secondary antibody was prepared in the same manner as the typical anti-mouse IgG
antibody, with the exception that it was run over an agarose column that contains rat IgG. As
a result, the final antibody stock is devoid of any anti-mouse IgG that may cross-react with rat
IgG. Slides were incubated in an avidin–biotin–peroxidase complex (ABC kit; Vector
Laboratories) for 1 h at RT and rinsed (3 × 5 min) in PBS followed by incubation with 3,3′–
diaminobenzidine (DAB; Sigma, St Louis, MO, USA) (12 mM final concentration in PBS with
0.003% H2O2), for 5–7 min to visualise ERα labelling. The slides were rinsed (2 × 5 min in
PBS), dehydrated, stained with Nissl (1.5 min exposure to 0.02% thionin), and coverslipped.
Western blot analysis
Protein extraction method to yield the cytoplasmic fraction of homogenised
prefrontal cortex—Frozen prefrontal cortical tissue from human, monkey and rat was
pulverised on dry ice and pre-weighed at approximately 0.5 g. Tissue was homogenised with
10 strokes of a Dounce homogeniser in 5 × vol/wt ice cold low salt lysis buffer [5 mM NaCl,
20 mM HEPES (pH 7.9), 1.5 mM MgCl2, 0.2 mM ethylenediaminetetraacetic acid, 0.1% Triton
X-100, 1 mM dithiothreitol, 5 µg/ml aprotinin, 0.5 mg/ml bacitracin, 40 µg/ml phenyl-
methysulphonyl fluoride (PMSF), 5 µg/ml pepstatin A, 5 µg/ml leupeptin]. All protease
inhibitors (aprotinin, pepstatin A, and leupeptin) were purchased from ICN (Aurora, OH)
except bacitracin, purchased from Sigma. The homogenates were then centrifuged at 14000
g for 10 min. at 4 °C, and the supernatants containing the crude, extra-nuclear (which we refer
to as the ‘cytoplasmic’ fraction, were collected, and stored in 10% glycerol at −80 °C whereas
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the remaining pellet containing the nuclear material was re-suspended, loaded with high salt
buffer, lysed, and stored frozen as described (4). Protein concentrations from each sample were
determined by spectrophotometry with a BCA protein assay kit (Pierce, Rockford, IL, USA).
SDS-PAGE and immunoblot detection—To determine the molecular weight of proteins
recognised by the ERα primary antibody used in the immunohistochemistry experiments, we
performed western blot analyses on the following preparations: (i) crude cytoplasmic fractions
from rat, monkey and human brain; (ii) MCF7 breast cancer cell lysate; (iii) T47D breast cancer
cell lysate; (iv) rat ovary extract (MCF7, T47D and rat ovary extracts were purchased from
Santa Cruz Biotechnologies); and (v) solutions containing baculovirus system derived, human
recombinant full-length ERα (approximately 62.80kDa; PV4543) or human recombinant full-
length ERβ (approximately 59.50kDa; PV4539), both purchased from PanVera Corp
(Madison, WI, USA). Rat and monkey cytoplasmic fractions were loaded at 50 µg per well;
human cytoplasmic fractions were loaded at 75 µg per well; MCF7, T47D and rat ovary lysates/
extracts were loaded at 50 µg per well; and full-length ERα and ERβ proteins were loaded at
0.4 µg per well. The mammalian cytoplasmic fractions and recombinant proteins were diluted
to their final protein concentrations in sample buffer (62.5 mM Tris, 10% glycerol, 2% SDS,
0.00125% bromophenol blue, and 5% β-mercaptoethanol). All samples were heated at 94 °C
for 4 min and then centrifuged. The samples were separated on 7.5% SDS-PAGE and
transferred to nitrocellulose membrane (Amersham Pharmacia Biotech, Piscataway, NJ, USA)
by electro-blotting. After blocking with 3% BSA in Tris-buffered saline (TBS) and 0.1%
Tween20 (blocking buffer) overnight at 4 °C, the membrane was incubated with NCL-ER6F11,
the same monoclonal 1° antibody used in the immunohistochemistry experiment, at a 1 : 50
dilution in blocking buffer overnight at 4 °C. The membrane was subsequently washed 8 × 5
min in TBS, 0.1% Tween20 (wash buffer) and then incubated with goat anti-mouse IgG
peroxidase-conjugated secondary antibody (1 : 10 000 dilution in blocking buffer; Chemicon
laboratories, Temecula, CA, USA) for 1 h. at RT and then again washed 6 × 5 min in wash
buffer. Immunopositive bands were visualised using Amersham ECL plus Chemiluminescent
Substrate Reagents (Piscataway, NJ, USA) and exposure to Kodak BioMax MR film (Eastman
Kodak Company, Rochester, NY, USA).
Preabsorption study
To determine the specificity of the ERα monoclonal antibody, the antibody (ER6F11) was pre-
incubated with recombinant full-length ERα or ERβ protein (described above). Increasing
amounts of recombinant protein were added to a fixed concentration of ERα antibody at a 1 :
1, 1 : 5 and 1 : 10 molar concentration of ER6F11 to molar concentration of full-length protein
(the 1 : 1 molar concentration was defined as 3.75 µg/ml ER6F11 with 3.26 µg/ml or 2.62 µg/
ml of ERα or ERβ respectively). The mixtures were gently rotated overnight at 4 °C in diluent.
The following day, the aforementioned methods for immunohistochemistry were performed
on serial sections from the same individual. For semi-quantitative evaluation of the
immunolabelling, sections were viewed under × 40 objective on a Zeiss Axiophot microscope
(Carl Zeiss MicroImaging, Inc., Thornwood, NY, USA) under constant illumination, and
images were captured with a digital camera using a random start point on the middle frontal
gyrus. ERα immunoreactivity in 20 neurones in layer V was determined by drawing an area
of interest around the cell body and applying an optical density scale using automated counting
tools from a Bioquant image analysis system (Nashville, TN, USA).
Immunoprecipitation
To further confirm the ER6F11 antibody specificity demonstrated with the western blot
analysis and preabsorption study, we immunoprecipitated DLPFC protein with the ER6F11
primary antibody and probed this immunoblot with a different primary ERα antibody (H-184,
sc-7207; Santa Cruz Biotechnologies). One hundred and fifty microgram of DLPFC protein,
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from the human brain, was pre-cleared by incubation with washed protein G sepharose beads
in NP-40 cell lysis buffer (50 mM Tris–HCl pH 8.0, 150 mM NaCl, 1% NP-40), PMSF (50 µg/
ml) and protease inhibitor cocktail [aprotinin (1 µg/ml), leupeptin (1 µg/ml), pepstatin (1 µg/
ml)]. The DLPFC protein was incubated on ice for 1 h with 25 µl of ER6F11 antibody. The
antibody–protein complexes were immunoprecipitated overnight at 4 °C, then incubated with
fresh protein G beads, the protein was eluted and prepared for western blotting, which was
carried out as described previously but with the Santa Cruz H-184 antibody at a 1 : 200 dilution.
Results
ERα positive cells in the human and monkey DLPFC and rat medial PFC
Neuronal ERα was detected by immunohistochemistry within the DLPFC of both humans and
monkeys and in the medial PFC of rat (Fig. 2B–D). Cellular ERα labelling was robust
throughout the cortical layers in all three species. A similar staining pattern with neuronal
labelling was observed in the human DLPFC with the Santa Cruz ERα antibody (data not
shown). In the absence of the Novo-castra ERα antibody, no background immunostaining was
observed in human DLPFC (Fig. 2A). Comparable results were observed in the absence of
primary antibody in monkey and rat prefrontal cortex (data not shown). Although the
immunostaining in the PFC is robust, it is unknown how the intensity of the immunodetection
relates to the absolute concentration of ERα protein in this region.
For humans and monkeys, strong ERα antibody labelling was observed in both pyramidal and
nonpyramidal shaped neurones throughout layers II–VI (Fig. 2B, C). Within layer I, labelling
was detectable in a small number of cells in all three species, but this labelling was fairly light.
In the primates, pyramidal neurones, especially in layer V, showed strong ERα
immunolabelling that was clearly observed in both the cytoplasm and nucleus (Fig. 3A, B).
Prominent ERα immunoreactivity was seen in neuronal nuclei in deeper cortical layers of the
rat (Fig. 3C). In both the human and the monkey cortex, the ERα protein distribution was found
in cytoplasm and nucleus (Fig. 3D, E, black arrows). In some neurones, the nucleus was
difficult to distinguish against the mottled cytoplasmic ERα labelling (Fig. 3F, white arrow
heads). Whether distribution was predominantly cytoplasmic or apparently equally distributed,
most neurones displayed punctate labelling in both areas. Intense ERα immunoreactivity could
sometimes be found in clumps near the outer cell membrane (Fig. 3D, E, white arrowheads),
or at the nuclear membrane (Fig. 3F). Additionally, in primate, ERα immunoreactivity
extended into the apical and basilar dendrites of most neurones (Fig. 3D–F, black arrowheads).
However, in the rat mPFC, only light ERα immunopositive label was found in the apical
dendrite (Fig. 3C). Overall, the relatively light labelling of the cytoplasm compared to the
nucleus in neurones in rat mPFC accentuated the nuclear labelling in rodent compared with
the primate. The subcellular distribution of ERα immunoreactivity varied from neurone to
neurone. In all three species, overall ERα antibody labelling was lighter in the subcortical white
matter and, although ERα immunoreactive neuropil appeared to stop abruptly at layer VI and
was absent from the forceps minor of the corpus callosum in the rat, ERα immunopositive cells
were detected in the subcortical white matter of humans (morphologically consistent with
interstitial white matter neurones).
To compare immunolabelling in the human DLPFC to other brain areas, we also examined the
human hippocampus, a region of abundant ERα (22) and the cerebellum, a region of sparse
ERα expression (23). Immunopositive neurones were found in all three brain regions (Fig. 4A–
C); however, as shown in previous studies on ERα mRNA in humans, ERα protein levels were
fairly low in the cerebellar cortex, specifically detected in Purkinje and Golgi cells, which
expressed low to moderate levels of ERα protein. Robust labelling of ERα immunopositive
pyramidal neurones were found in the hippocampus as has been reported previously (22), and
these neurones stained with similar intensity as pyramidal neurones in the PFC.
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Western blot analysis of prefrontal cortex and cell lysate
To confirm that the ERα protein localisation in PFC from the current study was specific to
ERα and not due to ERβ, western blot analyses were performed. The first western blot
demonstrates the specificity of the ERα antibody in preparations that contain ERα and/or
ERβ: two breast cancer cell lines (MCF7 and T47D), rat ovary and preparations of purified
recombinant ERα and ERβ. As seen in Fig. 5(A), the antibody recognised a protein band at
approximately 65–67 kDa (corresponding to the full-length ERα isoform) in cancer cell lysates
and in rat ovary. Furthermore, the antibody recognised recombinant ERα, but did not display
any affinity for the recombinant ERβ protein (compare lane 4 to lane 5). Several molecular
weight bands were recognised in addition to the expected 65–67 kDa band in rat ovary and in
breast cancer cell lines.
The second western blot assessed the size of ERα in cytoplasmic protein extracted from human,
monkey and rat frontal cortex. As seen in Fig. 5(B), the antibody recognised a 65–67 kDa band
in all three species studied. This observation supports the immunohistochemical findings;
namely, that the classical ERα protein can exist in the cytoplasmic or extranuclear compartment
of cells in all three mammalian species. In addition to detecting the predicted full-length protein
in brain, several immunoreactive bands were observed above and below the reported molecular
weight of 65–67 kDa (approximately 45–48, 51–55 and 94–98 kDa in molecular weight). The
pattern of immunoreactive bands found in the mammalian frontal cortex is similar to that found
in lysates from the MCF7 cell lines known to express many splice variants of ERα mRNA;
these ERα splice variants are also found in normal breast and normal brain (18, 24).
Antibody preabsorption studies with ERα and ERβ protein confirmed that the monoclonal
antibody is specific for ERα protein(s)
To further confirm that we were labelling ERα rather than ERβ, we performed
immunohistochemistry in human frontal cortical tissue after preabsorbing the antibody with
purified ERα or ERβ protein (Fig. 6A–C). Antibody alone produced a punctate labelling in the
neurones in all layers of the prefrontal cortex (Fig. 6A). When the antibody was preabsorbed
overnight with ERα protein, antibody labelling was greatly diminished (Fig. 6B). The results
from the semi-quantitative analysis of the ERα immunolabelling following preabsorption with
ERα and with ERβ proteins are displayed in Fig. 6(D). With increasing concentrations of the
full length ERα recombinant protein relative to primary antibody (1 : 1, 1 : 5 and 1 : 10 molar
ratio of ERα antibody concentration to recombinant protein concentration), the ERα
immunolabelling was significantly decreased compared to the immunolabelling with the
primary antibody alone, whereas two concentrations of ERβ recombinant protein (1 : 1 and 1 :
10) did not significantly block anti-ERα antibody immunoreactivity in neurones. The
diminution of the anti-ERα antibody signal with full-length ERα was significantly lower than
baseline at all three concentrations of recombinant ERα protein and showed a linear reduction
in staining up to five times the molar ratio of antigen to antibody. At a five-fold molar excess
of the recombinant ERα protein, we found levels of antibody staining that approached a
completely blocked antibody signal (approximately 80% diminished) but, at a ten-fold molar
ratio, the levels of the immunoreactivity began to increase. Preabsorption with ERβ protein
resulted in no diminution of ERα antibody labelling (Fig. 6C). Preabsorption with ERα protein
before immunohistochemistry in rat and monkey tissue yielded similar results (data not shown).
Immunoprecipitation with ER6F11 antibody confirmed that the monoclonal antibody is
specific for ERα protein(s)
To further demonstrate the specificity of the ER6F11 antibody used in our
immunohistochemistry experiments, we immunoprecipitated DLPFC protein extracts with
ERα ER6F11 then performed western blot analysis on the product with the Santa Cruz H-184
ERα antibody. We detected an immunopositive band at the predicted molecular weight of
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protein, approximately 65–67 kDa, suggesting that the two primary antibodies were indeed
capable of recognising the same ERα protein in brain. In addition, other smaller
immunoreactive bands were detected by the H-184 antibody after immunoprecipitation
(approximately 49 and 55 kDa). These results provide independent evidence that the
Novocastra antibody used in the present study detects at least three different forms of ERα in
brain and are consistent with findings from our original western blot, preabsorption studies,
and ERα mRNA studies.
Discussion
Our observation of fairly abundant ERα immunoreactivity in cortical neurones of the
mammalian PFC challenges the notion that ERα levels in this region are minimal or non-
existent. The high density of ERα immunolabelled cells found in our study contrasts with the
overall sparse ERα protein distribution found in some studies of rodent cortex (3,25). However,
our results are consistent with other immunolocalisation studies in rat cortex that find abundant
and widespread ERα protein in neurones (4,26). Furthermore, the detection of ERα protein in
the human frontal cortex supports our previous demonstration of ERα mRNA in the human
DLPFC by northern blotting, in situ hybridisation, and nested RT-PCR followed by direct
sequencing (16,18). We demonstrated that ERα mRNA is commonly found in both pyramidal
and nonpyramidal cortical neurones by in situ hybridisation (16). Although low to negligible
levels of ERα mRNA have been reported in the rat medial PFC (17), Pau et al. (15), showed
ERα mRNA expression by reverse transcriptase-polymerase chain reaction (RT-PCR) in the
adult frontal cortex of rhesus macaques. In addition, expression of ERα mRNA and protein in
BA46 of ovarectomised and oestrogen replaced female rhesus macaques was detected by in
situ hybridisation and immunohistochemistry by members of our group (2). Thus, although
published reports differ regarding the distribution of ERα protein and mRNA in mammalian
brain, many studies suggest that ERα protein present in the cortex.
The discrepancy between our finding of robust ERα protein and those of previous studies
showing low levels of ERα mRNA and protein in cortex may result from methodological
differences such as antibody specificity or concentration, riboprobe sensitivity, fixative choice
and tissue preparation. For example, the concentration of primary antibody used may be critical
in optimising ERα detection in fresh frozen tissue. Another methodological point to consider
is that our immunohistochemical signal is not completely blocked by pre-incubation with
ERα, suggesting that other proteins similar to ERα may contribute to the immunoreactive
signal. Alternatively, incubating the primary antibody with high levels of the full-length
ERα protein may artificially increase the background immunohistochemical signal. The ERα
component of the anti-ERα: ERα protein complexes formed during preabsorption could be
binding to other ERα binding partners such as steroid receptor coactivators in the tissue slice
(11) and this could increase the immunohistochemical signal at higher concentrations of ERα.
In the present study, we find robust ERα immunolabelling in the nucleus and cytoplasm. These
results concur with earlier and recent reports of both nuclear and cytoplasmic ERα
immunolabelling that can extend into the dendrites of brain neurones (2,3,22). González et
al. (27) reported ERα immunoreactivity in nucleus and cytoplasm of pyramidal neurones in
all layers of human adult temporal cortex and Mukai et al. (27) showed that ERα was located
in nuclei and cytoplasm within hippocampal neurones of rats. Consistent with other studies of
rodent cortex (4,26), we found prominent nuclear distribution of ERα in rat frontal cortex.
Cytoplasmic expression of ERα protein has been previously observed in a number of species,
including humans (28,29), monkey (2), and rat (30). Experimental studies in rodents suggest
that not only is ERα found in the spine heads and synaptic terminals of neurones, but also that
this cytoplasmic subcellular localisation is influenced by the age and the oestrogen status of
the animal (31). Additionally, some variant forms of ERα mRNA have been detected in the
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human and monkey DLPFC by splice variant specific RT-PCR (18). Some of these brain-
detected variants are unable to translocate to the nucleus in transfected cells and would be
expected to be exclusively cytoplasmic (19). Taken together, our results suggest that ERα
protein can be found in both the nucleus and cytoplasm in mammalian cortex and that the
ERα protein distribution may vary from neurone to neurone within the cortex.
Our western blot analysis reveals multiple ERα immunoreactive bands with molecular weights
that are consistent across the three species. In addition to the approximately 65 kDa ERα,
immunopositive bands of molecular weight above and below the full-length ERα were also
detected. The smaller immunoreactive bands at 49 and 55 kDa found in the frontal cortex of
these three species are similar to that found in lysates from the MCF7 cell lines and normal
tissue known to express splice variants of ERα mRNA (18,24). It could be argued that the
appearance of smaller molecular weight bands in human DLPFC are the result of protein
degradation during extended post-mortem intervals. We believe that this is not the case in the
present study because the monkey and rat cortical tissues were taken quickly after euthanasia
and the same ERα immunoreactive smaller-sized bands were also recognised. Furthermore,
smaller sized ERα bands were seen in the cell lysate preparations with no post-mortem interval.
The immunoreactivity observed in the present study therefore may represent the expression of
not only the classical ERα, but also smaller variant isoforms of ERα (32,33). Larger ERα
immunoreactive bands between 80 and 112 kDa have also been previously identified (28,33,
34). Various explanations may be offered for the appearance of these bands in western blots,
including longer splice variants (34), formation of homo- or heterodimers (35),
phosphorylation or ubiquitination (33) and complexes of ERα with any of its possible binding
partners (11). Thus, we may expect to see not only the classical ERα 66 kDa immunoreactive
band, but also additional isoforms.
As noted above, the identification of other isoforms or splice variants of ERα in native
mammalian tissue is not a novel finding. Studies characterising the ERα gene report the
production of several different mRNA transcripts in normal tissue (18,32). The relevance of
these alternate transcripts is suggested by observations that several of the proteins they encoded
have been found in rat uterus and pituitary (36,37). Some of the protein isoforms found in rat
uterus and pituitary are of particular interest because they are within the size range of the
ERα-like proteins identified in the present study. Furthermore, studies investigating the
function of variant ERα isoforms in vitro (19,38) suggest that the ERα-like proteins may be
physiologically meaningful and therefore, may be relevant to oestrogenic action in PFC.
In the present study, we describe ERα immunoreactivity in males; however, we may expect
similar findings in females. Indeed, cortical ERα immunoreactivity appears to be similar in
male and female rodents (3); sex differences were not found in cell number, intensity or
distribution of ERα immunoreactivity in rodent hippocampus or in adult human temporal
cortex (28). Additionally, our previous ERα mRNA studies in human PFC found no gender
difference in ERα mRNA levels (16). Similarly, ERα mRNA expression in male and female
rhesus macaque cortex were comparable (15) and cortical ERα mRNA levels do not differ by
gender using real-time PCR across the first month of postnatal life in mice (39). Behaviourally,
oestrogen or selective oestrogen receptor modulators appear to alter brain activation and/or
enhance task performance during PFC-influenced behavioural paradigms in male and female
humans (6,8,9).
Although behavioural and anatomical studies have provided a basis for inferring direct
oestrogen-mediated action in the PFC, the molecular mechanism for these actions (e.g.
genomic versus nongenomic actions) is not fully understood. Our results suggest that neuronal
ERα constitutes a viable molecular mediator of oestrogen action in the frontal cortex of
mammals. ERα protein was found in all layers of mammalian prefrontal cortex, prominent in
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neurones (both pyramidal and nonpyramidal) and not clearly identified in astrocytes. Using
parallel methodology, we have identified prominent ERα immunoreactivity in the DLPFC of
humans and monkeys as well as in the medial PFC of rats. Our observation confirms an earlier
report that also detected robust ERα immunolabelling throughout the cortex and highlights the
possibility that differences in methodology impact ERα detection in brain (4).
Although the effects of oestrogen can be mediated throughout oestrogen-sensitive
neurotransmitter systems that innervate the PFC such as serotonin and dopamine (40), our
detection of prominent ERα suggests that oestrogen can have direct effects on cortical
neurones. Indeed, oestrogen can alter spine number and spine morphology in frontal cortical
pyramidal neurones (41,42). However, the ER responsible for mediating oestrogen action in
pyramidal neurones in the primate frontal cortex was not determined in that study. The classical
mechanism of action for oestrogen is via its known intracellular receptors ERα and ERβ; either
or both may be involved. In the rodent PFC, ERβ mRNA expression is detectable and could
be expressed at higher levels than ERα mRNA (17,25), although the absolute molar abundance
of ERα and ERβ mRNA or protein in the mammalian frontal cortex is unknown. Thus, ERα
and ERβ may co-contribute to oestrogen binding, although we cannot exclude the possibility
that a novel ER transcript such as ER-X (43) or GPR30 (44) may play a role, particularly in
nongenomic signalling.
The localisation of ERα in PFC suggests that oestrogen may work via its classical intracellular
receptor (full-length and/or variant isoforms). The widespread subcellular distribution of these
ERα proteins in neurones (i.e. localised in both the cytoplasm and nucleus) suggests diverse
mechanisms of action. Expression in the nucleus suggests that ERα could serve in the classical
sense, as a transcription factor that directly modulates gene expression activity at oestrogen
response elements or indirectly modulates gene activation via interaction with other
transcription factors. Localisation of ERα outside the nucleus suggests that ERα may be
mediating some oestrogen-induced nongenomic efforts; for example, via the cAMP or similar
pathway (35). Moreover, the identification of possible ERα isoforms in the present study may
confer very different biological effects from the full-length protein, as demonstrated in clonal
cell lines (19). Future studies aimed at examining the molecular mechanism of cortical ERα
action in various mammalian species is expected to contribute significantly to our
understanding of oestrogenic action in the regulation of cognition and affect in humans.
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(A– C) Outline of coronal sections though the human, monkey, and rat frontal cortex. The
boxed area represents the area examined for each species. (A) coronal slice through the frontal
lobe of the human brain, the boxed area includes the superior frontal and middle frontal gyrus,
Brodmann’s area 46 of the dorsolateral prefrontal cortex (D, dorsal; V, ventral) is marked
(45); (B) coronal slice (Bregma’s coordinates 18.18–15.30 mm) though the monkey frontal
lobe, the boxed area includes the upper and lower banks of the principle sulcus, with
Brodmann’s area 46 marked (46); (C) coronal slice (Bregma’s coordinates 3.20–2.70 mm)
through the frontal cortex of the rat, the boxed area represents the medial frontal cortex, with
the infralimbic cortex (IL) and cingulate cortex areas 1 and 3 (Cg1 and Cg3) marked (47).
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(A–D). Photomicrographs of tissue sections after immunohistochemistry with the anti-
oestrogen receptor (ER)α antibody (B–D) showing robust immunolabel in the prefrontal cortex
of human, monkey and rat subjects. (A) In the absence of ERα antibody, no immunolabelling
(brown reaction product) is observed in human dorsolateral prefrontal cortex (DLPFC).
Labelling in the absence of ERα antibody in monkey and rat PFC display similar results (data
not shown). (B–D) Anti-ERα labelling is present throughout all layers of the prefrontal cortex.
(B) Robust ERα immunolabelling of cells of the human DLPFC is seen in layers II–VI and in
scattered cells in the subcortical white matter; (C) Robust ERα immunolabelling in monkey
DLPFC is found in all neuronal layers; (D) Robust ERα immunolabelling is found in rat medial
PFC. ERα protein localisation, indicated by brown staining.. Thionin, a Nissl stain, was used
to visualise the cytoarchitectural structure of the prefrontal cortex (blue staining) and reveals
that glial cells (dark blue Nissl) do not show a brown reaction product. Scale bar = 200 µm.
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(A–F). A higher magnification of neurones in prefrontal cortex (PFC) displays the subcellular
distribution of oestrogen receptor (ER)α. (A–C) Anti-ERα immunolabelling is observed in the
cytoplasmic and nuclear areas of neurones in the prefrontal cortex of all three species but not
in Nissl stained glia cells. ERα labelling in layer V of human and monkey dorsolateral (DL)
PFC and layer V of rat medial PFC. (A) In the human DLPFC punctuate immunoreactivity can
be seen in the cell soma and cellular processes of neurones; (B) In the monkey DLPFC, uneven
immunoreactivity can be detected in the cell soma and extends into the apical dendrites of
neurones; (C) In the rat PFC, nuclear ERα immunoreactivity is predominate, although some
label is seen in the cytoplasm. Scale bar = 25 µm and is representative of (A–C). (D–F) ERα
distribution is not homogeneous in every neurone in human DLPFC. Variation in the intensity
and apparent subcellular distribution of ERα immunolabelling in pyramidal neurones of layer
V is seen. ERα labelling in the cytoplasm appears darker than the nucleus in some neurones
(D–E, black arrow), clumps of immunoreactivity can be found along the outer cell membrane
(D, white arrowheads), whereas perinuclear (white arrowheads in F) and nuclear staining is
intense in other neurones. In all three neurones photographed, immunolabelling extends to the
apical dendrite (black arrowheads). There is also some ERα labelling extending into the basilar
dendrites (F, white arrow). Scale bar = 10 µm and is representative of (D–F).
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(A–C). Oestrogen receptor (ER)α immunolocalisation in human dorsolateral prefrontal cortex
(DLPFC), hippocampus, and cerebellum varies in intensity. ERα immunolabelling in layer III
of the DLPFC is intense in the cytoplasm of pyramidal neurones and extends into the apical
and basilar dendrites. (A) Light immunoreactivity is found in the cytoplasm of Purkinje cells
and Golgi cells of the human cerebellum; (B) robust immunoreactivity in cytoplasm and
processes of neurones in the hilar (CA4) and dentate gyrus regions of the human hippocampus;
(C) scale bar = 150 µm.
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(A–B) Western blot analysis reveals the expression of the full-length oestrogen receptor (ER)
α protein in prefrontal cortical tissue. (A) The ERα antibody is specific for ERα and does not
recognise ERβ. Novocastra ER6F11 detects the expected ERα protein expression in the MCF7
cell lysate (lane 1), rat ovary (lane 2), T47D cell lysate (lane 3) and the full-length recombinant
ERα (lane 5). The band at approximately 65–67 kDa is consistent with the classical full-length
ERα protein and can be detected in all lanes except in the lane where only recombinant ERβ
was present (lane 4). Lower molecular weight bands which vary in intensity according to the
sample are detected by the anti-ERα antibody (at 55 and 45 kDa), as well as one higher
molecular weight immunoreactive band (94 kDa). Molecular weight size markers in kDa are
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shown to the left of the figure. (B) Full-length ERa immunopositive proteins as well as smaller
ERα immunoreactive proteins are expressed in the prefrontal cortex of all three species.
Novocastra ER6F11was used to characterise ERα immunopositive proteins in the cytoplasmic
fractions from human, monkey and rat prefrontal cortical tissue. The band at approximately
65–67 kDa corresponds to the full-length ERα protein. The additional bands detected by the
antibody suggest additional ERα-like proteins identified with Novocastra ER6F11 in brain may
overlap with those detected in other tissues and cell lines (approximately 94, 51 and 45–48
kDa). Molecular weight size markers in kDa are shown to the left.
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(A–D) Immunohistochemistry after antibody preabsorption with full-length oestrogen receptor
(ER)α protein diminishes ERα antibody labelling in human dorsolateral prefrontal cortex
(DLPFC). The primary Novocastra ER6F11 antibody was preabsorbed overnight with full-
length ERα or full-length ERβ. Immunohistochemistry was performed with these antibody-
protein mixtures on human DLPFC. (A) ERα antibody alone; (B) ERα antibody preabsorbed
with 1× ERα protein; (C) ERa antibody preabsorbed with 1× ERβ protein. Scale bar = 50 µm
in (A–C); (D) bar graph showing the intensity of ER6F11 labelling in the presence and absence
of ERα and ERβ recombinant protein at 1 : 1 (× 1), 1 : 5 (× 5), and 1 : 10 (× 10) molar
concentrations of the ER6F11 primary antibody. The values in this graph represent the mean
total immunolabelling (error bars indicate the SEM). Overall ANOVA shows a significant block
of immunolabel at all three concentrations of ERα protein (× 1, × 5 and × 10) (F = 42.972, d.f.
= 6, 53, *P < 0.005). Immunohistochemistry with protein blocking was performed in monkey
and rat prefrontal cortex with similar results (data not shown).
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Table 1
Frozen DLPFC Post-Mortem Blocks were Obtained as Described in the Materials and Methods.
Subject characteristics for human post-mortem normal controls
Subject
Age
(years) Ethnicity/gender PMI (h) Cause of death
1 51 AA/M 6.5 Pneumonia
2 41 AA/M 14.5 SW
3 40 C/M 16 ASCVD
4 34 AA/M 13.5 GSW
5 43 AA/M 23 Hypertrophic Cardiomyopathy
6 42 AA/M 27.5 SW
7 49 AA/M 50.5 Diabetic Ketoacidosis
PMI, post-mortem interval; AA, African–American; C, Caucasian; M, Male; GSW, gun shot wound; SW, stab wound; ASCVD, atherosclerotic
cardiovascular disease
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